Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
The company is led by a management team experienced in the development and commercialization of rare disease therapeutics. Ultragenyx's strategy is predicated upon time- and cost-efficient drug development, with the goal of delivering safe and effective therapies to patients with the utmost urgency.NOVATO, Calif., Dec. 20, 2024 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), a biopharmaceutical company focused on the development and commercialization of novel therapies for rare and ultrarare diseases, today reported the grant of 15,175 restricted stock units of the company's common stock to 15 newly hired non-executive officers of the company. The awards were approved by the compensation committee of the company's board of directors and granted under the Ultragenyx Employment Inducement Plan, with a grant date of December 16, 2024, as an inducement material to the new employees entering into employment with Ultragenyx in accordance with Nasdaq Listing Rule 5635(c)(4).
加利福尼亞州諾瓦託，2024年12月20日（環球新聞稿）-- Ultragenyx Pharmaceutical Inc.（納斯達克：RARE）是一家專注於開發和商業化新型罕見病和超罕見病療法的生物製藥公司，今天報告向15名新聘用的非執行官授予15,175個受限制的股票單位。該獎勵已獲得公司董事會薪酬委員會的批准，並根據Ultragenyx員工誘導計劃授予，授予日期爲2024年12月16日，以作爲新員工根據納斯達克上市規則5635(c)(4)與Ultragenyx簽訂僱傭協議的誘因。
The restricted stock units vest over four years, with 25% of the underlying shares vesting on each anniversary of the grant date, subject to the employee being continuously employed by the company as of such vesting dates.
這些受限制的股票單位將在四年內逐漸歸屬，授予日期每週年的25%基本股份歸屬，前提是員工在該歸屬日期持續爲公司工作。
About Ultragenyx Pharmaceutical Inc.
Ultragenyx is a biopharmaceutical company committed to bringing novel products to patients for the treatment of serious rare and ultrarare genetic diseases. The company has built a diverse portfolio of approved therapies and product candidates aimed at addressing diseases with high unmet medical need and clear biology for treatment, for which there are typically no approved therapies treating the underlying disease.
關於Ultragenyx Pharmaceutical Inc.
Ultragenyx是一家生物製藥公司，致力於爲患者提供新型產品，以治療嚴重的罕見和超罕見遺傳疾病。該公司建立了一個多樣化的已批准療法和產品候選者組合，旨在解決具有高未滿足醫療需求和明確治療生物的疾病，通常這些疾病沒有批准的療法來治療其根本原因。
The company is led by a management team experienced in the development and commercialization of rare disease therapeutics. Ultragenyx's strategy is predicated upon time- and cost-efficient drug development, with the goal of delivering safe and effective therapies to patients with the utmost urgency.
該公司由一支有豐富罕見病治療藥物開發和商業化經驗的管理團隊領導。Ultragenyx 的策略基於及時高效的藥品研發，旨在以最大的緊迫性向患者提供安全有效的治療。
For more information on Ultragenyx, please visit the company's website at: .
欲了解更多有關Ultragenyx的信息，請訪問公司的官方網站：。
Contact Ultragenyx
Investors & Media
Joshua Higa
(415) 475-6370
聯繫Ultragenyx Pharmaceutical
投資者與媒體
約書亞·比嘉
(415) 475-6370
譯文內容由第三人軟體翻譯。